Здоровье без побочных эффектов - Питер Гётше (2013)

80. Harris G. Pfi zer says internal studies show no Celebrex risks. New York Times. 2005 Feb 5.

81. Caldwell B., Aldington S., Weatherall M., et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99: 132–40.

82. Sherman M., Marchione M. Pfizer: Celebrex raises heart attack risk. ABC News. 2004 Dec 17.

83. Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.

84. Avorn J. Dangerous deception – hiding the evidence of adverse drug effects. N Engl J Med. 2006; 355: 2169–71.

85. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.

86. Whitaker R. Anatomy of an Epidemic. New York: Broadway Paperbacks; 2010.

87. Smith S.M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2012; 8: CD001831.

88. Tomerak A.A.T., Vyas H.H.V., Lakhanpaul M., et al. Inhaled beta2-agonists for non-specific chronic cough in children. Cochrane Database Syst Rev. 2005; 3: CD005373.

89. Glintborg D. [Cough medicines for acute respiratory infections, what is the evidence?] Rationel Farmakoterapi. 2003 Jan 4.

90. Sharfstein J.M., North M., Serwint J.R. Over the counter but no longer under the radar – pediatric cough and cold medications. N Engl J Med. 2007; 357: 2321–4.

91. Public Health Advisory: FDA Recommends that Over-the-Counter (OTC) Cough and Cold Products not be used for Infants and Children under 2 Years of Age. 2011 Feb 23.

92. Parvez L., Vaidya M., Sakhardande A., et al. Evaluation of antitussive agents in man. Pulm Pharmacol. 1996; 9: 299–308.

93. Goodyear M.D., Lemmens T., Sprumont D., et al. Does the FDA have the authority to trump the Declaration of Helsinki? BMJ. 2009; 338: b1559.

94. Wikipedia. Tuskegee syphilis experiment. Available online at: (accessed 21 January 2010).

95. Boseley S., Smith D. As doctors fought to save lives, Pfizer flew in drug trial team. The Guardian. 2010 Dec 9.

96. Smith D. Pfizer pays out to Nigerian families of meningitis drug trial victims. The Guardian. 2011 Aug 12.

97. Chalmers T.C., Frank C.S., Reitman D. Minimizing the three stages of publication bias. JAMA. 1990; 263: 1392–5.

98. The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. 1980; 303: 1038–41.

99. Nissen S.E. Cardiovascular effects of diabetes drugs: emerging from the dark ages. Ann Intern Med. 2012; 157: 671–2.

100. Gøtzsche P.C., Liberati A., Luca P., et al. Beware of surrogate outcome measures. Int J Technol Ass Health Care. 1996; 12: 238–46.

101. Pocock S.J. When to stop a clinical trial. BMJ. 1992; 305: 235–40.

102. Moore T.J. Deadly Medicine: why tens of thousands of heart patients died in America’s worst drug disaster. New York: Simon & Schuster; 1995.

103. Gøtzsche P.C., Jørgensen K.J. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013; 6: CD001877.

104. D’Agostino R.B. Sr. Changing end points in breast-cancer drug approval – the Avastin story. N Engl J Med. 2011; 365: e2.

105. Pollack A. FDA revokes approval of Avastatin for use as breast cancer drug. New York Times. 2011 Nov 18.

106. Lenzer J. FDA is criticised for hinting it may loosen conflict of interest rules. BMJ. 2011; 343: d5070.

107. Psaty B.M., Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. JAMA. 2008; 299: 1474–6.

108. Heavey S. FDA warns Pfizer for not reporting side effects. Reuters. 2010 June 10.

109. Wise J. European drug agency criticises Roche for failing to report adverse reactions and patient deaths. BMJ. 2012; 344: e4344.